Akili’s Breakthrough in Digital Medicine
Akili’s Breakthrough in Digital Medicine:
Akili, a pioneer in therapeutic prescription digital medicine, has successfully secured $55 million in Series C financing. This follows the success of their trials for AKL-T01, a digital therapeutic designed to treat Attention Deficit Hyperactivity Disorder (ADHD). If approved, AKL-T01 will be the first standalone digital therapeutic for ADHD. Akili is also developing AKL-T02, aimed at treating Autism Spectrum Disorder (ASD).
Autism is a cognitive disorder, particularly in children, which affects social interaction due to repetitive behaviors and underdeveloped communication skills. The causes of autism are believed to be both genetic and environmental.
The recent funding will also advance Akili’s other projects, including treatments for multiple sclerosis (MS) and depression. Once approved by the U.S. Food and Drug Administration (FDA), AKL-T01 will be available commercially as a standalone ADHD treatment.
Akili’s CEO expressed satisfaction with the investor response, highlighting the company's potential in digital medicine. The company is focused on transforming healthcare through digital therapeutics that target cognitive disorders, using customized video games designed by neuroscientists. These games aim to improve specific brain functions affected by disorders like depression.
The success of AKL-T01 could pave the way for broader acceptance of digital therapeutic solutions, encouraging further investment and innovation in this field.
No comments:
Post a Comment